Rheumatoid arthritis - change of treatment after resolution of critical shortage of tocilizumab authority application form (PB324)

Use this form to apply for change of treatment from PBS-subsidised biological medicine to tocilizumab after resolution of critical shortage of tocilizumab for patients with rheumatoid arthritis.

You must download our forms to fill them in. We have help available if you use assistive technology or if you need a translator or interpreter. Find out how to use our forms.

You can upload this form in HPOS.

'Biological agent' refers to:

  • abatacept
  • adalimumab
  • baricitinib
  • certolizumab pegol
  • etanercept
  • golimumab
  • infliximab
  • rituximab
  • tofacitinib
  • upadacitinib.

Download and complete the Rheumatoid arthritis - change of treatment after resolution of critical shortage of tocilizumab authority application form.

Page last updated: 17 November 2022.
QC 55885